Afatinib

A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER.

Also Known As:

(2E)-N-(4-(3-Chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide; Afatinib Dimaleate; Afatinib Maleate; BIBW 2992; BIBW-2992; BIBW-2992-MA2; BIBW-2992MA2; BIBW2992; BIBW2992 MA2; Gilotrif; BIBW 2992 MA2; BIBW 2992MA2; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-

Networked: 1249 relevant articles (228 outcomes, 333 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yang, James Chih-Hsin: 25 articles (01/2022 - 05/2012)
2.	Solca, Flavio: 22 articles (01/2022 - 05/2007)
3.	Cseh, Agnieszka: 20 articles (04/2022 - 03/2015)
4.	Park, Keunchil: 20 articles (01/2022 - 05/2012)
5.	Schuler, Martin: 19 articles (01/2022 - 08/2012)
6.	Hirsh, Vera: 19 articles (01/2020 - 07/2011)
7.	Lu, Shun: 18 articles (01/2022 - 02/2014)
8.	Nakagawa, Kazuhiko: 17 articles (01/2022 - 06/2010)
9.	Wu, Yi-Long: 16 articles (04/2022 - 02/2014)
10.	Märten, Angela: 16 articles (01/2022 - 10/2014)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/01/2016 - "Whether a full dosage of afatinib is tolerable and effective for elderly or low performance status (PS) patients with advanced refractory non-small-cell lung cancer (NSCLC) is unclear. " 04/01/2015 - "Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion." 11/01/2016 - "Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). " 06/28/2014 - "Afatinib, an irreversible ErbB family blocker, was recently approved for the first-line treatment of EGFR mutation-positive metastatic non-small cell lung cancer. " 09/01/2013 - "Oral afatinib (Gilotrif™) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test. "
2.	Neoplasms (Cancer) 05/05/2023 - "Results showed that with minor structural modifications on afatinib, the inhibitory effect of NEP010 on EGFR mutant tumors was significantly improved. " 01/01/2021 - "This adds to the growing body of evidence suggesting that afatinib can be effective in patients with NRG1 fusion-positive tumors. " 01/01/2021 - "Afatinib is a pan-ErbB family inhibitor that may be an effective treatment for NRG1 fusion-driven tumors. " 09/01/2016 - "However, afatinib appeared to be especially effective for these tumors. " 01/01/2017 - "Afatinib is at least partially effective by triggering apoptosis of tumor cells. "
3.	Adenocarcinoma of Lung 01/01/2019 - "Moreover, use of afatinib may provide significantly improved PFS in patients with advanced lung adenocarcinoma with one of these two EGFR mutations." 01/01/2019 - "First-line afatinib treatment is beneficial for advanced lung adenocarcinoma patients with sensitive EGFR mutations. " 01/01/2020 - "Afatinib is an effective first-line treatment for patients with lung adenocarcinoma harboring complex EGFR mutations, especially those with uncommon mutation patterns." 01/01/2019 - "Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations." 01/01/2018 - "Afatinib exhibits therapeutic efficacy for lung adenocarcinoma patients harboring HER2 exon 20 insertions. "
4.	Lung Neoplasms (Lung Cancer) 08/07/2008 - "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models." 11/14/2017 - "In this study, we compared the therapeutic efficacy in lung cancer patients of a regimen of 40 mg/day of afatinib with that of a lower dose regimen of <40 mg/day resulting either from a lower starting dose of 30 mg/day or dose adjustment. " 01/01/2019 - "Immunochemotherapy was effective and improved the patient's performance status while afatinib controlled the progression of lung cancer. " 08/08/2019 - "To study the effect of SPP1 on afatinib resistance, siSPP1 was used to knock down SSP1 in afatinib-resistant lung cancer cells. " 06/01/2019 - "Although afatinib inhibited the growth of lung cancer cells with low T790M allele frequencies in preclinical studies, this could not be translated into clinical efficacy in terms of lowering the rate or delaying the time of T790M acquisition."
5.	Neoplasm Metastasis (Metastasis) 01/01/2021 - "In addition, afatinib as first-line treatment was associated with a longer PFS whereas a relatively younger age and no brain metastasis at diagnosis were associated with better OS." 03/01/2018 - "Afatinib, a second-generation EGFR-TKI, is also effective against central nervous system(CNS)metastasis of NSCLC. " 01/01/2016 - "First-line afatinib was also effective in patients with certain uncommon EGFR mutation and patients with central nervous system metastasis. " 01/01/2015 - "Afatinib may therefore be an effective treatment for heavily pretreated patients with EGFR-mutated or EGFR-TKI-sensitive NSCLC and CNS metastasis." 01/01/2015 - "First-line afatinib is also effective in patients with central nervous system (CNS) metastasis. "

Related Drugs and Biologics

1.	ErbB Receptors (EGF Receptor)
2.	Erlotinib Hydrochloride (CP 358,774)
3.	Tyrosine Kinase Inhibitors
4.	Gefitinib (Iressa)
5.	osimertinib
6.	Cisplatin (Platino)
7.	Gemcitabine
8.	Platinum
9.	Pemetrexed (MTA)
10.	Cetuximab (Erbitux)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Time-to-Treatment
4.	Radiotherapy
5.	Drug Tapering